23.67
Elanco Animal Health Inc stock is traded at $23.67, with a volume of 6.39M.
It is up +5.15% in the last 24 hours and down -7.36% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
See More
Previous Close:
$22.51
Open:
$22.75
24h Volume:
6.39M
Relative Volume:
0.98
Market Cap:
$11.83B
Revenue:
$4.89B
Net Income/Loss:
$-242.00M
P/E Ratio:
-48.40
EPS:
-0.489
Net Cash Flow:
$315.00M
1W Performance:
+7.01%
1M Performance:
-7.36%
6M Performance:
-5.81%
1Y Performance:
+31.50%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ELAN
Elanco Animal Health Inc
|
23.67 | 11.06B | 4.89B | -242.00M | 315.00M | -0.489 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
7th Circ. Won't Revive Elanco Investors' Securities Fraud Suit - Law360
Is Elanco Animal Health Inc (ELAN) Overvalued After 5.2% Rally? - GuruFocus
Elanco Investors Fail to Revive Sales Misrepresentation Suit (2) - Bloomberg Law News
5 Must-Read Analyst Questions From Elanco’s Q2 Earnings Call - Yahoo Finance
Elanco Animal Health (NYSE:ELAN) Director Buys 5,000 Shares - MarketBeat
Elanco Animal Health (ELAN) director purchases 5,000 shares of stock - Stock Titan
Elanco rating upgraded by Fitch on deleveraging progress - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Elanco Animal Health expands US screwworm response - foxbusiness.com
Elanco (ELAN): Innovation Is Turning A Leveraged Portfolio Into A Share-Taking Platform - Seeking Alpha
Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Elanco Animal Health (ELAN) Insider Buying: EVP and CFO Robert V - GuruFocus
Elanco's CLiK(TM) Extra (Dicyclanil Topical Suspension) Wound Spray Receives FDA Emergency Use Authorization for Application on or Around Wounds for Prevention of New World Screwworm in Variety of Livestock and Captive and Captured Wildlife Speci - ACCESS Newswire
Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Buys $96,936.00 in Stock - MarketBeat
Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock - MarketBeat
ELAN Stock Jumps As Earnings Beat Fuels Bullish Guidance - StocksToTrade
Elanco Animal Health (NYSE: ELAN) EVP granted new deferred stock units - Stock Titan
Elanco (ELAN) CFO boosts stake with 4,200-share buy and new Deferred Stock Units - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons receives new deferred stock unit grant - Stock Titan
Elanco Animal Health (NYSE: ELAN) director buys 10,000 shares at $23.69 - Stock Titan
Bank of America Corp DE Has $80.36 Million Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Does Elanco (ELAN) Have a Durable Edge in Animal Health After Its Screwworm EUA Win? - Yahoo! Finance Canada
Elanco Animal Health (ELAN) Following FDA Emergency Use Authorization Has Valuation Back In Focus - Yahoo Finance
INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigati - The National Law Review
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Elanco Animal Health Q2 Earnings Call Highlights - MarketBeat
elanco animal health inc. Positive Earnings Pre-Announcements - RTTNews
ELAN Looks 42.8% Overvalued on GF Value™ - GuruFocus
Elanco Animal Health Inc (ELAN) Shares Fall 8.6% -- GF Value Says Still Overvalued - GuruFocus
Elanco Animal Health Incorporat (ELAN) Stock forecasts - Yahoo Finance UK
ELAN Looks 35.7% Overvalued on GF Value™ as Market Prices in Fut - GuruFocus
Elanco wound spray can help protect livestock from screwworm - Stock Titan
Elanco Animal Health (NYSE:ELAN) Sees Unusually-High Trading Volume on Analyst Upgrade - MarketBeat
Elanco Ends Lobbying Relationship With Stumptown Strategies - Legis1
Amundi Has $2.35 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Cetera Investment Advisers Buys 65,526 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
UBS Adjusts Price Target on Elanco Animal Health to $33 From $31, Maintains Buy Rating - Moomoo
Elanco Animal Health Inc (ELAN) Shares Fall 7.7% -- What GF Scor - GuruFocus
Elanco CEO on Boosted Forecast, Surge in Tick Bites - Yahoo Finance
Elanco raises 2026 outlook after strong second-quarter results - Feed Strategy
UBS Group Boosts Elanco Animal Health (NYSE:ELAN) Price Target to $33.00 - marketbeat.com
Why Elanco Animal Health (ELAN) Stock Is Down Today - quiverquant.com
Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, KeyCorp Analyst Says - MarketBeat
Elanco Animal Health Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Elanco Animal Health (ELAN) Stock Eyes Margin Momentum As Debt Questions Linger - simplywall.st
Elanco Animal Health Incorporat (ELAN) Stock Forecasts - Yahoo! Finance Canada
Elanco Animal Health CEO Jeff Simmons goes one-on-one with Jim Cramer - cnbc.com
Elanco Animal Health Inc (ELAN) (Q2 2026) Earnings Call Highligh - GuruFocus
Elanco Animal Health (NYSE:ELAN) Announces Earnings Results - MarketBeat
Elanco Animal Health Inc (ELAN) (Q2 2026) Earnings Call Highlights: Strong Innovation Drives 8% ... - Yahoo Finance
Elanco Sees Strong Pet Health Momentum, Bets on Innovative Products - Benzinga
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elanco Animal Health Inc Stock (ELAN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| VanHimbergen Robert M | EVP and CFO |
Aug 07 '26 |
Buy |
23.08 |
4,200 |
96,926 |
137,516 |
| Herendeen Paul | Director |
Aug 07 '26 |
Buy |
23.68 |
10,000 |
236,850 |
111,687 |
| Modi Rajeev A. | SEE REMARKS |
May 15 '26 |
Buy |
20.35 |
4,911 |
99,939 |
160,812 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
May 15 '26 |
Buy |
20.09 |
4,971 |
99,843 |
171,971 |
| Kurzius Lawrence Erik | Director |
Dec 12 '25 |
Buy |
21.30 |
10,000 |
213,000 |
131,773 |
| Modi Rajeev A. | SEE REMARKS |
Dec 11 '25 |
Buy |
21.33 |
4,500 |
95,985 |
123,082 |
| VanHimbergen Robert M | EVP and CFO |
Dec 11 '25 |
Buy |
21.64 |
6,950 |
150,426 |
124,233 |
| Simmons Jeffrey N | PRESIDENT, CEO AND DIRECTOR |
Dec 11 '25 |
Buy |
21.75 |
22,000 |
478,496 |
167,000 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):